NIB (ASX:NHF) share price wobbles after ACCC drops court case

The NIB Holdings Limited (ASX: NHF) share price is has been up and down since the ACCC agreed to drop court proceedings against the insurer.

The NIB Holdings Limited (ASX: NHF) share price is up and down after the Australian Competition and Consumer Commission (ACCC) withdrew court proceedings against the health insurer.

Following NIB's update at 3:22 pm AEST yesterday, the company's shares rallied briefly before closing the day 0.16% lower at $6.23. The S&P/ASX 200 Index (ASX: XJO) also ended the day lower by 1.06%.

This morning, the NIB share price opened around 2% lower before partially recovering to its current level of $6.20, down 0.48% for the day so far.

Let's take a closer look at the announcement.

good news and bad for asx shares represented by same man pictured happy and then sad

Image source: Getty Images

ACCC drops case against NIB

In a statement to the ASX on Tuesday afternoon, NIB said the ACCC would end court proceedings against the company that began in May 2017.

The case was brought about due to changes in NIB's 'MediGap Scheme', a program in which the company would cover out-of-pocket costs for customers using Medicare services that were not bulk billed.

The ACCC alleged NIB failed to notify customers that it would no longer cover certain eye procedures under the scheme in 2015. The government body further alleged customers then unwittingly undertook these procedures, unaware they were no longer covered by the policy.

The trial was delayed due to a similar case the ACCC had against Medibank Private Ltd (ASX: MPL). It was then further delayed due to the COVID-19 pandemic.

The ACCC said it agreed to drop the charges as NIB had made the necessary changes since the proceedings first began. 

ACCC chair Rod Sims commented:

Given the passage of time since this case was commenced, NIB's changed notification practice during that time and the improvements made across the industry as a result of the ACCC's interventions in the sector, we believe it is no longer in the public interest to continue proceedings against NIB. 

We are pleased the industry has significantly changed practices since 2015 to ensure greater transparency for consumers, including NIB's change of its approach and commitment to continue informing customers about changes that may affect their out–of–pocket expenses for ongoing treatment ahead of the changes occurring.

In its statement, NIB said it "is committed to acting in the best interests of its members and has denied the ACCC's allegations."

NIB share price snapshot

Over the past 12 months, the NIB share price has increased by around 31%. Only last week, shares in the company were in the green after it sold its digital healthcare advisory platform.

NIB has a market capitalisation of $2.85 billion.

Motley Fool contributor Marc Sidarous has no position in any of the stocks mentioned. The Motley Fool Australia has recommended NIB Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Two pharmacist talking to each other.
Healthcare Shares

How much could the Sigma Healthcare share price rise in the next year?

Could this stock deliver healthy returns?

Read more »

A business man wearing a life jacket prepares to jump off a sinking boat
ASX Share Market News

ASX 200 utilities and healthcare shares win the week again

This is the second week in which these traditionally defensive market sectors outperformed.

Read more »

Happy healthcare workers in a lab.
Healthcare Shares

Mesoblast reports Ryoncil revenue surge and improved cash spend

Mesoblast reported a 44% jump in Ryoncil revenue and a substantial improvement in operating cash spend.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

Down 44%: Will you regret not buying Pro Medicus shares?

The shares have fallen hard, but the business itself continues to grow at an impressive rate.

Read more »

Two colleagues looking at a graph and comparing share prices.
Healthcare Shares

CSL shares: Buy, hold, or sell?

The shares have recovered sharply, so I wanted to see whether the valuation still stacks up.

Read more »

Two colleagues looking at a graph and comparing share prices.
Healthcare Shares

Telix vs Clinuvel Pharmaceuticals: Which ASX healthcare share deserves your next $1,000 of investment capital?

We compare Telix and Clinuvel Pharmaceuticals on valuation, dividends, and momentum—which ASX healthcare stock looks more compelling now?

Read more »

Numerous Australian dollar notes laid out.
Healthcare Shares

I'd buy 6,462 shares of this ASX stock to aim for $200 a month of passive income

This business can provide very healthy dividends.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

UBS thinks Telix Pharmaceuticals shares will go how high?

Good news out of the US has led to a share price target upgrade.

Read more »